GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Accelrys, Inc. (ACCL) [hlAlert]

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting
angiotensin and endothelin receptor antagonist for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered program currently in Phase 2 clinical trials targeting chronic obstructive pulmonary disease and four partnered programs in Phase 1 clinical trials targeting rheumatoid arthritis, oncology, metabolic and inflammatory diseases. Four additional partnered compounds are in preclinical development.
( Total: 7 Current Stock Recommendations )
Accelrys, Inc.   (7)
Hold 29% Buy 71%
Related companies
DARA BIOSCIENCES   (2)
Buy 100%
CELSION CORP   (6)
Buy 100%
China Biologic ...   (4)
Buy 100%
ATHERSYS INC   (7)
Buy 100%
ACURA PHARMACEUTICAL   (2)
Buy 100%
China Pharma   (2)
Buy 100%
BioSpecifics ...   (5)
Buy 100%
Derma Sciences, Inc.   (2)
Buy 100%
Tenax Therapeutics ...   (2)
Buy 100%
ARCA BIOPHARMA INC.   (1)
Buy 100%
Filter by Gains:   
  
Rating:
Hold ACCL
Accelrys, Inc. (ACCL) rated Hold by Craig Hallum
Friday,  Jan 31, 2014  8:25 AM ET

Rating:
Hold ACCL

Rating:
Buy ACCL
up 55.01 %

Rating:
Buy ACCL
up 60.17 %

Rating:
Buy ACCL
up 50.54 %

Rating:
Hold ACCL

Rating:
Buy ACCL
up 90.99 %

Rating:
Hold ACCL
Accelrys, Inc. (ACCL) rated Neutral by Dougherty & Company
Monday,  Dec 22, 2008  1:25 PM ET

Rating:
Buy ACCL
up 177.38 %

Rating:
Buy ACCL
down 2.64 %

Your Recent Stocks
SymbolLastChange
ACCL 12.51   0.00 %

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy